Amicus Therapeutics disclosed a preclinical Chaperone-Advanced Replacement Therapy program for MPS I

Amicus Therapeutics disclosed a preclinical Chaperone-Advanced Replacement Therapy (CHART™) program for MPS I. Amicus is developing a proprietary human recombinant IDUA (rhIDUA) enzyme co-formulated with a novel pharmacological chaperone as a next-generation therapy for MPS I.

Read the full press release.

This entry was posted in News. Bookmark the permalink.

Comments are closed.